Kronos Bio

Summary

The company is dedicated to developing therapeutics that target dysregulated transcription, which is linked to cancer and autoimmune diseases. Their innovative approach involves analyzing transcriptional regulatory networks to identify critical nodes for drug development. They have several clinical candidates in their pipeline, including a CDK9 inhibitor for MYC-dependent tumors and a KAT inhibitor for Sjögren’s disease, and they collaborate with Genentech for further advancements in oncology.